Canoga Perkins Brings Breakthrough Private 5G Technology to the BLOQUE Innovation Hub in Queretaro, Mexico
28.1.2026 14:00:00 CET | Business Wire | Press release
Canoga Perkins, a global leader in Private 5G network connectivity solutions, announces their first international Private 5G Customer Experience Center at the BLOQUE in Queretaro, Mexico. On January 16th, 2026 the company demonstrated the SyncMetra® 100 product and an end-to-end Private 5G solution at the “Experiencing SyncMetra®” event attended by government representatives, city representatives, industry leaders, technology partners, system integrators, resellers and end customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128847071/en/
Querétaro invests in becoming a global hub for advanced manufacturing, industrial automation, smart agriculture and tech advanced ports applications; the demand for reliable, high-speed connectivity has never been higher. SyncMetra® 100 and Canoga Perkins arrive as critical enablers of Deterministic Networking for all these applications. The SyncMetra Platform offers a software-defined, IT-operated 5G network transport solution that guarantees the ultra-low latency required for next-generation industrial applications.
Revolutionizing Connectivity in Mexico – Unlike traditional wireless solutions, SyncMetra is purpose-built to support Time Sensitive Networking (TSN). This capability allows enterprises to deploy various mission critical applications —such as robotic control, Enterprise AI, and AR/VR, manufacturing and automation—without the lag or instability inherent in standard cellular or Wi-Fi networks. As part of the event, Canoga Perkins demonstrated an industrial robotic arm operating flawlessly over an Ultra-Low Latency Private 5G Network supported by SyncMetra.
"Bringing SyncMetra to Mexico is a major milestone for Canoga Perkins and we are gratified by the overwhelming response from industry leaders here," said Malik Arshad, President of Canoga Perkins. "Deterministic networking removes the barriers to digital transformation for the most critical applications. The Bloque is a venue for furthering technology, innovation and digital entrepreneurship. It’s fitting that we are demonstrating that deterministic Private 5G and 5G TSN are no longer future concepts— we take pride in developing leading edge solutions that show that these technologies are ready for deployment today."
Key Technology Highlights:
- Determinism: Guaranteed Quality of Service (QoS) for real-time industrial communication.
- Ultra-Reliable Low-Latency (URLLC): Precise packet delivery essential for mission-critical automation.
- IT-Centric Operation: Cloud-managed orchestration via SyncMetra Manager™ (SMM) for ease of use.
- Scalable Architecture: Expands easily to cover large manufacturing floors or complex campus environments.
About the Bloque
BLOQUE is the Innovation and Technology Center of the Municipality of Querétaro, promoted by the Ministry of Innovation and Technology. It is a unique public space in Mexico, designed so that anyone – students, entrepreneurs, professionals, companies and organizations – can learn, create and connect through technology, innovation and talent training. In BLOQUE, citizens find the tools to build tomorrow. We are the space that invites you to create, not just observe. Here ideas come to life and dreams are transformed. We are more than a place: we are the community of the future.
Find out more: BLOQUE - ¿Qué es BLOQUE?
About Canoga Perkins
With over five decades of engineering excellence, Canoga Perkins has consistently led the charge in delivering mission-critical network solutions that empower industries to innovate and thrive. Trusted by leading service providers, industrial enterprises, utilities, military branches, and government agencies, Canoga Perkins combines a rich legacy with a relentless drive for innovation. We lead with AI whenever possible, designing intelligent solutions that are not only reliable and secure but also scalable and adaptable, ensuring our clients are always at the forefront of technological advancement.
Learn more at www.canogaperkins.net.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260128847071/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom